Bayer Heralds Potential Of BlueRock Parkinson's Stem Cell Therapy
Early-Stage Signs Show Promise
Executive Summary
Bayer pharma research head Christian Rommel has told Scrip he was excited about the Phase I data on Parkinson's disease prospect bemdaneprocel, which is comprised of dopamine-producing neurons derived from pluripotent stem cells, but also advocated caution at this early stage.
You may also be interested in...
AskBio Declares Independence After Bayer Acquisition
The gene therapy specialist's CEO Sheila Mikhail tells Scrip she is excited to be getting access to the German group's late-stage clinical and operational expertise while keeping AskBio's entrepreneurial culture and carrying on as an autonomous company on an arm’s-length basis.
Bayer Eyes Indications Beyond BlueRock's Initial Focus With $240m-Plus Buyout
Bayer will acquire the 40.8% of BlueRock that it doesn't already own as the firm's largest investor via a $225m series A round in 2016. A clinical trial for BlueRock's Parkinson's disease candidate is expected to begin later this year.
All Systems Go At Almirall To Enter Tough Atopic Dermatitis Market With Ebglyss
Following a positive opinion from the CHMP, the Spanish company is hoping to launch its challenger to Dupixent in the EU before the end of the year.